Apollo is partnering with and taking a minority stake in Sofinnova Partners with plans to commit €1 billion ($1 billion) of managed capital to Sofinnova’s investment funds that concentrate on European life sciences investments.
The new partnership is slated to offer entrepreneurs an expanded range of capital solutions to help bring new therapeutic and biotechnology-based solutions to the market, officials said. The investment capital slated for Sofinnova vehicles includes future strategies the firms may develop together.
For Sofinnova, the deal allows them access to Apollo’s global investment platform that includes $513 billion . . .
Unlock this article instantly, along with the rest of our premium content and benefits including daily/weekly/monthly newsletters.
A pay-as-you-go plan to get you started
→ Instantly unlock all new and archived articles
→ Daily, weekly and monthly e-mail newsletters
→ Access to the weekly AW Deal Watch by AW Research
Get more for less - 20% discount over monthly
→ Everything in Monthly PLUS:
→ Access to articles and data from AW Research
→ AW Annual Investor Compendium – our comprehensive guide to investor activity, with a ranking of the most active investors for the year and profiles of the top global allocators